Celcuity Reports Q3 2026 Financial Results and Revtopik Commercial Launch Progress
Celcuity (CELC) reported its third quarter 2026 financial results, highlighting the initial commercial launch of Revtopik, which became available on September 30. While the company reported no revenue for the quarter due to timing, early adoption metrics are strong: 78% of top strategic accounts have already ordered the therapy, and 91% of U.S. commercial and Medicare lives are covered by payers. The company experienced a net loss of $73.3 million ($1.33 per share), an increase from $43.8 million in the prior year period, driven primarily by $77.3 million in operating expenses related to Revtopik's commercialization and infrastructure. Despite the losses, Celcuity maintains a robust cash position of $642.7 million, which management expects will fund operations through 2029.
Topics: breast cancer treatment market adoption product launch revenue guidance